Dr Ulli Backofen
Boehringer Ingelheim
Referent:innen
Dr. Thomas Fürst
Boehringer Ingelheim
Dr. Josef Hofer
exdra
Dr. Cornelia Nopitsch-Mai
formerly Quality Assessor
Dr. Bettina Pahlen
Quality x Pharma Consulting
Dr Thomas Uhlich
Bayer
Dr. Heiko Brunner
Hamburg
Zielsetzung
Setting Specifications and Acceptance Criteria:
This event covers all aspects of specifications for Active Pharmaceutical Ingredients (APIs = Drug Substances), biological substances and pharmaceutical drug products from an analytical and a registration perspective.
In the workshops the participants will elaborate specifications
- for drug substance and drug product based on different case studies,
- specifications of biotechnological drug substances / drug products – general part
- specifications of biotechnological drug substances / drug products – related to the impurity profiles
These example specifications will be useful “take home messages” which will help the participants to define or to evaluate specifications in their daily work.
Stability Testing for Drug Substances and Drug Products:
This event is intended to provide information on different aspects of stability testing. The conference will be opened by an overview of stability testing with a special focus on important changes in current revisions of ICH Guidelines. In the subsequent presentations, important aspects of stability testing for biologicals and throughout drug development are discussed. The second day commences with a lecture on stability testing for Drug Substances, followed by a talk on Drug Products and a risk based approach for stability testing covering different climatic zones. In the following presentation, the focus lies on to the various aspects of submitting stability data. The specific challenges of data evaluation and typical questions from authorities will also be addressed. Finally, statistical considerations will be covered in another lecture.
Hintergrund
In the development of new pharmaceutical products it is a great challenge to establish meaningful and reasonable specifications, which are scientifically sound and appropriate for APIs (chemical and biological drug substances), excipients and drug products. According to ICH Guideline Q6A, a specification is defined as a list of tests, references to analytical procedures, and appropriate acceptance criteria, which are numerical limits, ranges, or other criteria for the tests described. Learn about latest news and important aspects of excipients, such as functionality testing (EP and USP) as well as what GMP-level is requested for excipients. Concentrate on the essentials for packaging material including important information to be included in the CTD.
The analytical result, which will be compared to the specification, is affected by the variability of the measurement itself and depends also on the sampling process and on the variability of the manufacturing process of the tested product itself. This makes statistical considerations essential and consideration of the associated measurement uncertainties vital when setting or complying with specifications.
Analytical methods that were not “stability-indicating” are frequently cited in FDA 483s and Warning Letters. This conference will thus address how to set impurity limits for related substances and degradation products based on method capability and stability results. Furthermore, genotoxic impurities and strategies for their control will be presented and QbD (Quality by Design) will also be discussed.
Finally, specifications for the API (drug substance), excipient(s) and the drug product are part of the quality section of the marketing authorisation application which has to be submitted to the competent authority.
Zielgruppe
This conference is of particular interest to specialists from QA, QC and Regulatory Affairs departments of the API and pharmaceutical industry and CROs as well as to members of the EU inspectorates and authorities. Participants have the opportunity to exchange their experiences they gained with the different aspects of ‘specifications’ with the experts from the API and pharmaceutical industry as well as with members of competent authorities.
Programm
Gesamtes Programm als PDF herunterladen
Part I - Regulatory Requirements and Setting Specifcations during the Development Phase
Basic Principles for Setting of Release and Shelf-Life Specifications
- Some basic statistics: Distribution and Variation
- Variation and specifications
- Changes over time and shelf life specification
- Process Capability
- Control strategy
- QbD or not to be
Current Regulatory Requirements for Setting Specifications (ICH Q6A)
- Regulatory overview
- Impact of pharmacopoeial provisions
- Setting specifications for active substances and finished products
- Justification of specifications
- Changes/variations
- Introduction to the requirements of risk assessment with focus on setting specifications for heavy metals
- How authorities will proceed in respect of submitting the required documentation for approved marketed products
Specifications of Biopharmaceuticals
- Overview of regulatory requirements
- Critical Quality attributes and Control Strategy
- Differences between NCEs and NBEs
- Considerations for Drug Substance and Drug Product
- Specifications during early and late stage development
- Acceptance criteria at release and for shelf life
Organic Impurities and Degradation Products with Special Emphasis on Genotoxic Impurities
- What do the guidelines tell us
- Impurity identification and profiling
- Impurity tracking
- Toxicological qualification
- Genotoxic impurities
- Control of genotoxic impurities
Part II – Chemical APIs and Biopharmaceutical Drug Development
Parallel Session A (Lectures and Workshops)
CHEMICAL APIs
Group I: APIs Manufactured by Chemical Synthesis
Lecture and Workshop
Rational Development and Justification of API Specfications
- In this workshop participants will elaborate specifications comprising typical tests for APIs:
- Assay, organic impurities and degradation products, water, residual solvents, heavy metals, particle size distribution, polymorphs, genotoxic impurities etc.
BIOLOGICALS
Group II: Drug Substances/Drug Products Manufactured by Biotechnological Processes – Part 1
Group II: Drug Substances/Drug Products Manufactured by Biotechnological Processes – Part 1
Lecture and Workshop
Setting Specifications in early Biopharmaceutical Drug Development (with a special focus on Monoclonal Antibodies)
- General overview of manufacturing processes for biopharmaceuticals and process Control
- Analytical testing scope for biopharmaceuticals
- How to set specifications: principles to consider and justification
- Group Work
Part III – Specific Considerations during Development and for Specific Dosage Forms
Setting Specifications throughout Drug Development
- Specifications throughout development
- Specifications in Pharmacopoeias
- Stability of the manufacturing process
- Specifications for comparator products
Specifications for Specific Drug Products – What is the Difference to Standard Formulations
- Specific aspects required for special drug products, e.g.
- Gastro-intestinal therapeutic systems (GITS) or osmotic-controlled release oral delivery systems (OROS)
- Transdermal Patches
- Orally inhaled and nasal drug products (OINDPs)
Part IV – Drug Products and Biological Impurities
Parallel Session B (Lectures and Workshops)
DRUG PRODUCTS
Group I: Drug Products Containing APIs (manufactured by chemical synthesis)
Lecture and Workshop
Rational Development and Justification of Drug Products Specifications
- In this workshop participants will elaborate specifications comprising typical tests for different types of drug products, e.g. assay, purity, content uniformity, dissolution, fill volume, endotoxines, sterility etc.
BIOLOGICALS
Group II: Drug Substances/Drug Products Manufactured by Biotechnological Processes – Part 2
Group II: Drug Substances/Drug Products Manufactured by Biotechnological Processes – Part 2
Lecture and Workshop
Impurities in Biological Drug Substances and Drug Products (with a special focus on Monoclonal Antibodies)
- Impurities from chemical synthesis versus biotechnological process
- Definition of impurities and their classification: productrelated impurities, process-related impurities, contaminants and identification of possible degradation products
- How to deal with impurities in biological drug substances and drug products
- Analytical techniques and other aspects
Part V – Common Technical Document (CTD)
Setting Specifications in the CTD
- Total Control Strategy and Regulatory Background
- Drug Substances, Excipients and Drug Products
- Packaging materials
- Which information should be included in the CTD
- Typical questions from authorities and answers
*********************************
Current ICH and CHMP Guidelines for Stability Testing
- Overview of Stability Guidelines
- Concepts of Stability testing
- Retest period and Shelf-life
- Post-marketing Stability Studies
- Future Activities
Stability Testing for Biologicals
- Overview of regulatory requirements
- Types of stability studies for Biopharmaceuticals
- Practical aspects of stability studies with Biopharmaceuticals
- Degradation pathways
- Setting shelf life during early and late stage development
Stability Testing throughout Drug Development
- Must the development stability programme meet ICH Q1A?
- Stability testing from early development to product launch
- Clinical stability for comparators
- Site specific stability
Stability Testing for Drug Substances
- Stability protocols
- Stress testing
- Photostability testing
- Documentation
Stability Testing for Drug Products
- Strategy of Stability Testing
- Performance of new Drug Products
- Related Finished Products with existing substances
- Follow-up Stability Testing
Submitting Stability Data
- Regulatory Strategy Stability
- Drug Substance and Drug Product Stability Data and Evaluation
- Storage recommendations/labelling/SmPC
- Stability studies, commitments post approval
- Typical questions from authorities and answers
Evaluation of Stability Results – Statistical Considerations
- Sample number and replication
- Trend analysis
- Outliers
- Pooling of batch data
- Shelf life prediction
| ECA-Member*: | € 2790,- |
| Non ECA Member*: | € 2990,- |
| EU/GMP Inspectorates*: | € 1495,- |
| APIC Member Discount*: | € 2890,- |
Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.
* auch unkompliziert per Kreditkarte bezahlbar
Weitere Termine vor Ort
Weitere Termine vor Ort nicht verfügbar
Weitere Termine online
Weitere Termine online nicht verfügbar
Aufzeichnung nicht verfügbar
Haben Sie noch Fragen?
Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de
Teilnehmerstimmen - das sagen andere über unsere Seminare:
